ID   RUNX3_HUMAN             Reviewed;         415 AA.
AC   Q13761; B1AJV5; Q12969; Q13760;
DT   02-NOV-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1999, sequence version 2.
DT   18-JUN-2025, entry version 230.
DE   RecName: Full=Runt-related transcription factor 3;
DE   AltName: Full=Acute myeloid leukemia 2 protein;
DE   AltName: Full=Core-binding factor subunit alpha-3;
DE            Short=CBF-alpha-3;
DE   AltName: Full=Oncogene AML-2;
DE   AltName: Full=Polyomavirus enhancer-binding protein 2 alpha C subunit;
DE            Short=PEA2-alpha C;
DE            Short=PEBP2-alpha C;
DE   AltName: Full=SL3-3 enhancer factor 1 alpha C subunit;
DE   AltName: Full=SL3/AKV core-binding factor alpha C subunit;
GN   Name=RUNX3; Synonyms=AML2, CBFA3, PEBP2A3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=7622058; DOI=10.1016/0378-1119(95)00060-j;
RA   Bae S.-C., Takahashi E., Zhang Y.-W., Ogawa E., Shigesada K., Namba Y.,
RA   Satake M., Ito Y.;
RT   "Cloning, mapping and expression of PEBP2 alpha C, a third gene encoding
RT   the mammalian Runt domain.";
RL   Gene 159:245-248(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=7835892; DOI=10.1006/geno.1994.1519;
RA   Levanon D., Negreanu V., Bernstein Y., Bar-Am I., Avivi L., Groner Y.;
RT   "AML1, AML2, and AML3, the human members of the runt domain gene-family:
RT   cDNA structure, expression, and chromosomal localization.";
RL   Genomics 23:425-432(1994).
RN   [3]
RP   SEQUENCE REVISION.
RA   Groner Y.;
RL   Submitted (FEB-1999) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 95-148.
RX   PubMed=7607690; DOI=10.1016/0888-7543(95)80185-o;
RA   Wijmenga C., Speck N.A., Dracopoli N.C., Hofker M.H., Liu P., Collins F.S.;
RT   "Identification of a new murine runt domain-containing gene, Cbfa3, and
RT   localization of the human homolog, CBFA3, to chromosome 1p35-pter.";
RL   Genomics 26:611-614(1995).
RN   [8]
RP   INTERACTION WITH TLE1.
RX   PubMed=9751710; DOI=10.1073/pnas.95.20.11590;
RA   Levanon D., Goldstein R.E., Bernstein Y., Tang H., Goldenberg D.,
RA   Stifani S., Paroush Z., Groner Y.;
RT   "Transcriptional repression by AML1 and LEF-1 is mediated by the
RT   TLE/Groucho corepressors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:11590-11595(1998).
RN   [9]
RP   INTERACTION WITH SUV39H1.
RX   PubMed=16652147; DOI=10.1038/sj.onc.1209591;
RA   Reed-Inderbitzin E., Moreno-Miralles I., Vanden-Eynden S.K., Xie J.,
RA   Lutterbach B., Durst-Goodwin K.L., Luce K.S., Irvin B.J., Cleary M.L.,
RA   Brandt S.J., Hiebert S.W.;
RT   "RUNX1 associates with histone deacetylases and SUV39H1 to repress
RT   transcription.";
RL   Oncogene 25:5777-5786(2006).
RN   [10]
RP   INTERACTION WITH FOXP3.
RX   PubMed=17377532; DOI=10.1038/nature05673;
RA   Ono M., Yaguchi H., Ohkura N., Kitabayashi I., Nagamura Y., Nomura T.,
RA   Miyachi Y., Tsukada T., Sakaguchi S.;
RT   "Foxp3 controls regulatory T-cell function by interacting with
RT   AML1/Runx1.";
RL   Nature 446:685-689(2007).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-243, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [12]
RP   FUNCTION, INTERACTION WITH ZFHX3, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=20599712; DOI=10.1016/j.bbrc.2010.06.090;
RA   Mabuchi M., Kataoka H., Miura Y., Kim T.S., Kawaguchi M., Ebi M.,
RA   Tanaka M., Mori Y., Kubota E., Mizushima T., Shimura T., Mizoshita T.,
RA   Tanida S., Kamiya T., Asai K., Joh T.;
RT   "Tumor suppressor, AT motif binding factor 1 (ATBF1), translocates to the
RT   nucleus with runt domain transcription factor 3 (RUNX3) in response to TGF-
RT   beta signal transduction.";
RL   Biochem. Biophys. Res. Commun. 398:321-325(2010).
RN   [13]
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION, AND INTERACTION WITH SRC; FYN AND
RP   LCK.
RX   PubMed=20100835; DOI=10.1074/jbc.m109.071381;
RA   Goh Y.M., Cinghu S., Hong E.T., Lee Y.S., Kim J.H., Jang J.W., Li Y.H.,
RA   Chi X.Z., Lee K.S., Wee H., Ito Y., Oh B.C., Bae S.C.;
RT   "Src kinase phosphorylates RUNX3 at tyrosine residues and localizes the
RT   protein in the cytoplasm.";
RL   J. Biol. Chem. 285:10122-10129(2010).
RN   [14]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-192, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
CC   -!- FUNCTION: Forms the heterodimeric complex core-binding factor (CBF)
CC       with CBFB. RUNX members modulate the transcription of their target
CC       genes through recognizing the core consensus binding sequence 5'-
CC       TGTGGT-3', or very rarely, 5'-TGCGGT-3', within their regulatory
CC       regions via their runt domain, while CBFB is a non-DNA-binding
CC       regulatory subunit that allosterically enhances the sequence-specific
CC       DNA-binding capacity of RUNX. The heterodimers bind to the core site of
CC       a number of enhancers and promoters, including murine leukemia virus,
CC       polyomavirus enhancer, T-cell receptor enhancers, LCK, IL3 and GM-CSF
CC       promoters (By similarity). May be involved in the control of cellular
CC       proliferation and/or differentiation. In association with ZFHX3, up-
CC       regulates CDKN1A promoter activity following TGF-beta stimulation
CC       (PubMed:20599712). CBF complexes repress ZBTB7B transcription factor
CC       during cytotoxic (CD8+) T cell development. They bind to RUNX-binding
CC       sequence within the ZBTB7B locus acting as transcriptional silencer and
CC       allowing for cytotoxic T cell differentiation. CBF complexes binding to
CC       the transcriptional silencer is essential for recruitment of nuclear
CC       protein complexes that catalyze epigenetic modifications to establish
CC       epigenetic ZBTB7B silencing (By similarity). Necessary for the
CC       development and survival of sensory neurons expressing parvalbumin (By
CC       similarity). {ECO:0000250|UniProtKB:Q64131,
CC       ECO:0000269|PubMed:20599712}.
CC   -!- SUBUNIT: Heterodimer with CBFB. RUNX3 binds DNA as a monomer and
CC       through the Runt domain. DNA-binding is increased by heterodimerization
CC       (By similarity). Interacts with TLE1 and SUV39H1 (PubMed:16652147,
CC       PubMed:9751710). The tyrosine phosphorylated form (via runt domain)
CC       interacts with SRC (via protein kinase domain) (PubMed:20100835).
CC       Interacts with FYN and LCK (PubMed:20100835). Interacts with FOXP3
CC       (PubMed:17377532). Interacts with ZFHX3 (PubMed:20599712). Interacts
CC       with TBX21 (By similarity). {ECO:0000250|UniProtKB:Q64131,
CC       ECO:0000269|PubMed:16652147, ECO:0000269|PubMed:17377532,
CC       ECO:0000269|PubMed:20100835, ECO:0000269|PubMed:20599712,
CC       ECO:0000269|PubMed:9751710}.
CC   -!- INTERACTION:
CC       Q13761; P25440: BRD2; NbExp=8; IntAct=EBI-925990, EBI-2874802;
CC       Q13761; Q13951: CBFB; NbExp=3; IntAct=EBI-925990, EBI-718750;
CC       Q13761; P35222: CTNNB1; NbExp=12; IntAct=EBI-925990, EBI-491549;
CC       Q13761; Q09472: EP300; NbExp=7; IntAct=EBI-925990, EBI-447295;
CC       Q13761; P56524: HDAC4; NbExp=9; IntAct=EBI-925990, EBI-308629;
CC       Q13761; Q9UQL6: HDAC5; NbExp=5; IntAct=EBI-925990, EBI-715576;
CC       Q13761; Q5U5Q3: MEX3C; NbExp=4; IntAct=EBI-925990, EBI-2864451;
CC       Q13761; Q9NQB0: TCF7L2; NbExp=14; IntAct=EBI-925990, EBI-924724;
CC       Q13761; Q04724: TLE1; NbExp=3; IntAct=EBI-925990, EBI-711424;
CC       Q13761-2; Q13951: CBFB; NbExp=3; IntAct=EBI-12145465, EBI-718750;
CC       Q13761-2; Q96NT3-2: GUCD1; NbExp=3; IntAct=EBI-12145465, EBI-11978177;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00399,
CC       ECO:0000269|PubMed:20100835, ECO:0000269|PubMed:20599712}. Cytoplasm
CC       {ECO:0000269|PubMed:20100835, ECO:0000269|PubMed:20599712}. Note=The
CC       tyrosine phosphorylated form localizes to the cytoplasm. Translocates
CC       from the cytoplasm to the nucleus following TGF-beta stimulation.
CC       {ECO:0000269|PubMed:20599712}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q13761-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q13761-2; Sequence=VSP_005949;
CC   -!- TISSUE SPECIFICITY: Expressed in gastric cancer tissues (at protein
CC       level). {ECO:0000269|PubMed:20599712}.
CC   -!- DOMAIN: A proline/serine/threonine rich region at the C-terminus is
CC       necessary for transcriptional activation of target genes.
CC   -!- PTM: Phosphorylated on tyrosine residues by SRC. Phosphorylated by LCK
CC       and FYN. {ECO:0000269|PubMed:20100835}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Z35278; CAA84541.1; -; mRNA.
DR   EMBL; X79550; CAA56093.2; -; mRNA.
DR   EMBL; AL023096; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL445471; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471134; EAW95148.1; -; Genomic_DNA.
DR   EMBL; BC013362; AAH13362.1; -; mRNA.
DR   EMBL; U14520; AAA86465.1; -; Genomic_DNA.
DR   CCDS; CCDS257.1; -. [Q13761-1]
DR   CCDS; CCDS30633.1; -. [Q13761-2]
DR   PIR; B55563; B55563.
DR   PIR; S60078; S60078.
DR   RefSeq; NP_001026850.1; NM_001031680.2. [Q13761-2]
DR   RefSeq; NP_001307601.1; NM_001320672.1. [Q13761-2]
DR   RefSeq; NP_004341.1; NM_004350.3. [Q13761-1]
DR   RefSeq; XP_005246081.1; XM_005246024.5. [Q13761-2]
DR   RefSeq; XP_047289087.1; XM_047433131.1. [Q13761-2]
DR   PDB; 5W69; X-ray; 2.80 A; I/J/K/L=133-141.
DR   PDBsum; 5W69; -.
DR   AlphaFoldDB; Q13761; -.
DR   SMR; Q13761; -.
DR   BioGRID; 107312; 73.
DR   CORUM; Q13761; -.
DR   ELM; Q13761; -.
DR   FunCoup; Q13761; 4330.
DR   IntAct; Q13761; 23.
DR   MINT; Q13761; -.
DR   STRING; 9606.ENSP00000382800; -.
DR   GlyCosmos; Q13761; 11 sites, 1 glycan.
DR   GlyGen; Q13761; 12 sites, 1 O-linked glycan (11 sites).
DR   iPTMnet; Q13761; -.
DR   PhosphoSitePlus; Q13761; -.
DR   SwissPalm; Q13761; -.
DR   BioMuta; RUNX3; -.
DR   DMDM; 17368453; -.
DR   jPOST; Q13761; -.
DR   MassIVE; Q13761; -.
DR   PaxDb; 9606-ENSP00000382800; -.
DR   PeptideAtlas; Q13761; -.
DR   ProteomicsDB; 59677; -. [Q13761-1]
DR   ProteomicsDB; 59678; -. [Q13761-2]
DR   Antibodypedia; 1124; 717 antibodies from 42 providers.
DR   DNASU; 864; -.
DR   Ensembl; ENST00000308873.11; ENSP00000308051.6; ENSG00000020633.19. [Q13761-1]
DR   Ensembl; ENST00000338888.4; ENSP00000343477.3; ENSG00000020633.19. [Q13761-2]
DR   Ensembl; ENST00000399916.5; ENSP00000382800.1; ENSG00000020633.19. [Q13761-2]
DR   GeneID; 864; -.
DR   KEGG; hsa:864; -.
DR   MANE-Select; ENST00000308873.11; ENSP00000308051.6; NM_004350.3; NP_004341.1.
DR   UCSC; uc001bjq.4; human. [Q13761-1]
DR   AGR; HGNC:10473; -.
DR   CTD; 864; -.
DR   DisGeNET; 864; -.
DR   GeneCards; RUNX3; -.
DR   HGNC; HGNC:10473; RUNX3.
DR   HPA; ENSG00000020633; Tissue enhanced (bone marrow, lymphoid tissue).
DR   MIM; 600210; gene.
DR   OpenTargets; ENSG00000020633; -.
DR   VEuPathDB; HostDB:ENSG00000020633; -.
DR   eggNOG; KOG3982; Eukaryota.
DR   GeneTree; ENSGT00940000156598; -.
DR   HOGENOM; CLU_032910_3_0_1; -.
DR   InParanoid; Q13761; -.
DR   OMA; TQGLWPE; -.
DR   OrthoDB; 10029800at2759; -.
DR   PAN-GO; Q13761; 8 GO annotations based on evolutionary models.
DR   PhylomeDB; Q13761; -.
DR   PathwayCommons; Q13761; -.
DR   Reactome; R-HSA-4411364; Binding of TCF/LEF:CTNNB1 to target gene promoters.
DR   Reactome; R-HSA-8941855; RUNX3 regulates CDKN1A transcription.
DR   Reactome; R-HSA-8941856; RUNX3 regulates NOTCH signaling.
DR   Reactome; R-HSA-8941858; Regulation of RUNX3 expression and activity.
DR   Reactome; R-HSA-8949275; RUNX3 Regulates Immune Response and Cell Migration.
DR   Reactome; R-HSA-8951430; RUNX3 regulates WNT signaling.
DR   Reactome; R-HSA-8951671; RUNX3 regulates YAP1-mediated transcription.
DR   Reactome; R-HSA-8951911; RUNX3 regulates RUNX1-mediated transcription.
DR   Reactome; R-HSA-8951936; RUNX3 regulates p14-ARF.
DR   Reactome; R-HSA-8952158; RUNX3 regulates BCL2L11 (BIM) transcription.
DR   SignaLink; Q13761; -.
DR   SIGNOR; Q13761; -.
DR   BioGRID-ORCS; 864; 18 hits in 1173 CRISPR screens.
DR   CD-CODE; 1A18FFC4; Paraspeckle.
DR   CD-CODE; 8C2F96ED; Centrosome.
DR   ChiTaRS; RUNX3; human.
DR   GeneWiki; RUNX3; -.
DR   GenomeRNAi; 864; -.
DR   Pharos; Q13761; Tbio.
DR   PRO; PR:Q13761; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q13761; protein.
DR   Bgee; ENSG00000020633; Expressed in granulocyte and 163 other cell types or tissues.
DR   ExpressionAtlas; Q13761; baseline and differential.
DR   GO; GO:0000785; C:chromatin; ISS:BHF-UCL.
DR   GO; GO:0016513; C:core-binding factor complex; TAS:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; NAS:UniProtKB.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; TAS:ProtInc.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISS:BHF-UCL.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; ISS:BHF-UCL.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL.
DR   GO; GO:0001222; F:transcription corepressor binding; IPI:UniProtKB.
DR   GO; GO:0002062; P:chondrocyte differentiation; IBA:GO_Central.
DR   GO; GO:0030097; P:hemopoiesis; IBA:GO_Central.
DR   GO; GO:0043371; P:negative regulation of CD4-positive, alpha-beta T cell differentiation; ISS:UniProtKB.
DR   GO; GO:0045786; P:negative regulation of cell cycle; ISS:UniProtKB.
DR   GO; GO:0050680; P:negative regulation of epithelial cell proliferation; ISS:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; ISS:BHF-UCL.
DR   GO; GO:0030182; P:neuron differentiation; IBA:GO_Central.
DR   GO; GO:0001503; P:ossification; IBA:GO_Central.
DR   GO; GO:0048935; P:peripheral nervous system neuron development; TAS:BHF-UCL.
DR   GO; GO:0043378; P:positive regulation of CD8-positive, alpha-beta T cell differentiation; ISS:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0045595; P:regulation of cell differentiation; IBA:GO_Central.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; NAS:UniProtKB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0071559; P:response to transforming growth factor beta; IDA:UniProtKB.
DR   FunFam; 2.60.40.720:FF:000001; Runt-related transcription factor; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   InterPro; IPR000040; AML1_Runt.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd_sf.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR013524; Runt_dom.
DR   InterPro; IPR013711; RunxI_C_dom.
DR   InterPro; IPR016554; TF_Runt-rel_RUNX.
DR   PANTHER; PTHR11950; RUNT RELATED; 1.
DR   PANTHER; PTHR11950:SF43; RUNT-RELATED TRANSCRIPTION FACTOR 3; 1.
DR   Pfam; PF00853; Runt; 1.
DR   Pfam; PF08504; RunxI; 1.
DR   PIRSF; PIRSF009374; TF_Runt-rel_RUNX; 1.
DR   PRINTS; PR00967; ONCOGENEAML1.
DR   SUPFAM; SSF49417; p53-like transcription factors; 1.
DR   PROSITE; PS51062; RUNT; 1.
DR   neXtProt; NX_Q13761; -.
DR   PharmGKB; PA34886; -.
DR   TreeFam; TF321496; -.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; Cytoplasm; DNA-binding;
KW   Isopeptide bond; Nucleus; Phosphoprotein; Proteomics identification;
KW   Reference proteome; Transcription; Transcription regulation;
KW   Ubl conjugation.
FT   CHAIN           1..415
FT                   /note="Runt-related transcription factor 3"
FT                   /id="PRO_0000174662"
FT   DOMAIN          54..182
FT                   /note="Runt"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00399"
FT   REGION          1..48
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          176..266
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          375..415
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        186..205
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        209..240
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        393..402
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        406..415
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         243
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18220336"
FT   CROSSLNK        192
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1..5
FT                   /note="MRIPV -> MASNSIFDSFPTYSPTFIR (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_005949"
FT   CONFLICT        249
FT                   /note="D -> V (in Ref. 2; CAA56093)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        253
FT                   /note="P -> S (in Ref. 2; CAA56093)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        256
FT                   /note="P -> S (in Ref. 2; CAA56093)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        259
FT                   /note="T -> S (in Ref. 2; CAA56093)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        268..269
FT                   /note="MH -> IY (in Ref. 2; CAA56093)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        271
FT                   /note="P -> T (in Ref. 2; CAA56093)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        297..298
FT                   /note="MP -> IS (in Ref. 2; CAA56093)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   415 AA;  44356 MW;  593FBFB3C4639BBD CRC64;
     MRIPVDPSTS RRFTPPSPAF PCGGGGGKMG ENSGALSAQA AVGPGGRARP EVRSMVDVLA
     DHAGELVRTD SPNFLCSVLP SHWRCNKTLP VAFKVVALGD VPDGTVVTVM AGNDENYSAE
     LRNASAVMKN QVARFNDLRF VGRSGRGKSF TLTITVFTNP TQVATYHRAI KVTVDGPREP
     RRHRQKLEDQ TKPFPDRFGD LERLRMRVTP STPSPRGSLS TTSHFSSQPQ TPIQGTSELN
     PFSDPRQFDR SFPTLPTLTE SRFPDPRMHY PGAMSAAFPY SATPSGTSIS SLSVAGMPAT
     SRFHHTYLPP PYPGAPQNQS GPFQANPSPY HLYYGTSSGS YQFSMVAGSS SGGDRSPTRM
     LASCTSSAAS VAAGNLMNPS LGGQSDGVEA DGSHSNSPTA LSTPGRMDEA VWRPY
//
